Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7407.164 (Published 17 July 2003) Cite this as: BMJ 2003;327:164
  1. Edward A Nardell (enardell@pih.org), associate professor
  1. Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02115, USA

    EDITOR—In their decision analysis Sterling et al hypothesise but offer no evidence that the efficacy of DOTS (directly observed treatment, short course) has ever been diminished by DOTS-plus.1 On the contrary, under the current rigorous procedure for obtaining second line drugs at drastically reduced prices, the Green Light Committee of the World Health Organization assures that only programmes with demonstrably strong DOTS and DOTS-plus components are approved, …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription